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ABSTRACT
Objectives To determine if there is an association 
between acuity level of care (ALC), case fatality and length 
of stay in patients admitted to hospital due to COVID-19.
Design A hospital- based observational follow- up study.
Setting Internal Medicine Service of the Aga Khan 
University Hospital, Pakistan, from 26 February 2020 to 30 
June 2020.
Participants Adult patients with confirmed COVID-19, 
aged ≥18 years.
Methods ALC was categorised into low, intermediate 
and high level and patients were triaged using the 
standard emergency severity illness score. All patients 
were followed until the end of hospital admission for the 
outcome of case fatality and length of stay.
Results A total of 822 patients with COVID-19 were 
admitted during the study period and 699 met inclusion 
criteria. The mean age was 54.5 years and 67% were 
males; 50.4% were triaged to low, 42.5% to intermediate 
and 7.2% to high acuity care. The overall case- fatality rate 
was 11.6%, with the highest (52%) in high acuity level 
followed by 16.2% in intermediate and 2% in low acuity 
care. Acuity level was associated with case fatality, with an 
HR (95% CI) of 5.0 (2.0 to 12.1) for high versus low acuity 
care and an HR of 2.7 (1.2, 6.4) for intermediate versus 
low acuity care, after adjusting for age, sex and common 
comorbidities including diabetes, hypertension, ischaemic 
heart disease and chronic lung disease. Similarly, acuity 
level was also associated with length of hospital stay.
Conclusion High and intermediate acuity level is 
associated with higher case fatality rate and prolonged 
length of hospital stay in patients admitted with COVID-19. 
In resource- limited settings where the provision of high 
acuity care is limited, the intermediate care acuity could 
serve as a useful strategy to treat relatively less critical 
patients with COVID-19.
INTRODUCTION
COVID-19 is caused by SARS- CoV-2, the novel 
coronavirus, which rapidly converted into a 
pandemic causing global concern.1–3 More 
than 26 million cases were reported until 9 
September 2020, of which 871 166 died.4 
Preparing to combat this pandemic is more 
challenging for low- income and middle- 
income countries (LMICs) such as Pakistan 
with a population of over 212 million and 
a total health expenditure of only 2.6% of 
the gross domestic product. The first case 
of COVID-19 was reported in Karachi on 26 
February 2020, and although population- 
based screening for COVID-19 was not 
done, 298 509 cases had been reported with 
an overall mortality of 2.5%.5 Availability of 
critical care units and trained healthcare 
staff for managing patients with COVID-19 
due to limited resources is a major challenge 
for hospitals in Pakistan. Due to this limita-
tion, some critical patients are admitted to 
intermediate care units instead, who do not 
require urgent invasive ventilation. However, 
the outcome of these COVID-19 patients in 
terms of fatality or progression of the infec-
tion has not been reported thus far.
Acuity level of care (ALC) to patients is 
defined as an attribute of severity, inten-
sity paired with patient, provider or system, 
according to Holzemer’s Outcomes Model 
for Health Care Research.6 Besides, it also 
Strengths and limitations of this study
 ► This study determines the link between acuity level 
of care and case fatality and length of stay in pa-
tients with COVID-19 in a lower–middle- income 
country.
 ► This observational follow- up study and data extract-
ed from medical records reduce possible recall bias 
and selection bias.
 ► It is a single- centre hospital- based study and can-
not be generalised to the fatality rates in the general 
population.
 ► Clinical and laboratory details of patients are not re-
ported in detail in this study.
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encompasses physical, psychological and nursing care 
needs, workload and complexity, urgency and triage scales. 
ALC level in healthcare is linked with patients’ safety and 
mortality.7 8 An adequate number of beds with the right 
level of acuity to manage potentially critical patients with 
COVID-19 is therefore crucial to decrease suffering and 
avoid high mortality. However, whether the level of acuity, 
more specifically of intermediate care units, is linked 
to a favourable or less favourable outcome in patients 
with COVID-19 is not well known and especially not in 
LMIC. The WHO reports that 80% of those infected by 
SARS- CoV-2 develop mild symptoms, 14% have severe 
symptoms and 6% will complicate into a critical disease.9 
In a crisis situation such as the COVID-19 pandemic, 
institutional- based algorithms can aid clinicians to triage 
patients more efficiently.10 Due to the acute shortage of 
ventilators that many LMICs are facing, the decision to 
admit patients to high acuity becomes difficult.11 Also, in 
such LMICs triaging and admitting to the correct level 
of care is not only important for patient outcomes but 
also helps in prioritising healthcare resources efficiently. 
In general, patients triaged as having a higher ALC 
require a greater number of emergency or admitting 
service resources.12 Hence, ALC is an indirect measure 
of the severity of illness of patients and required health-
care resources to manage them. Illness severity scores 
are linked to the acuity of hospital settings.13 Five‐level 
systems such as the Emergency Severity Index (ESI) and 
the Canadian Triage Acuity System are considered more 
reliable than three‐level systems and are commonly used 
to triage based on the severity of illness and acuity.14 15
The Centers for Disease Control(CDC) and Prevention, 
USA, categorises patients with COVID-19 requiring hospi-
talisation into three levels of patient acuity.16 Non- acute 
care means general, low‐level care for mild- to- moderately 
symptomatic patients who may require oxygen (less than 
or equal to 2 L/min) but does not require extensive 
nursing care; mid- level care for moderately symptomatic 
patients means patients who require high oxygen support 
(more than 2 L/min), nursing care and assistance with 
activities of daily living and high acuity care for patients 
means patients who require significant ventilatory 
support, including intensive monitoring. Case fatality or 
length of hospital stay concerning the three ALC has not 
been reported in detail. The case fatality reported for 
patients with COVID-19 shows large variability. Studies 
have reported mortality ranging from 2% to 50%.3 17 The 
discrepancies in mortality might arise from differences 
in age groups affected, the testing capacity and whether 
there were massive screenings.18 Also, in a systematic 
review of 52 studies, the majority from China, median 
length of hospital stay ranged from 4 to 53 days within 
China and 4 to 21 days outside of China.19
In Pakistan, a significant number of critically ill 
patients are admitted to intermediate or special care 
units (SCU) due to a shortage of intensive care unit 
beds.20 However, there is no empirical evidence of 
favourable or unfavourable outcomes of patients 
with COVID-19 admitted to various ALC, specifically 
intermediate care units, from LMIC. Recognising the 
correct ALC required for patients with COVID-19 and 
determining their outcome is important, first because 
patients in COVID-19 units are alone without family 
members. Second, in settings with limited resources 
patients who need high acuity care could be cared for 
in intermediate care units with more vigilance and 
gain favourable outcome compared with not finding 
high acuity care at all. Third, the cost is an additional 
important factor. In LMIC such as Pakistan, patients 
are paying out of their pocket and high acuity care is 
more expensive than lower levels of ALC. We hypoth-
esise that recognising the correct level of acuity at 
the time of admission for COVID-19- positive patients 
in LMIC such as Pakistan is linked to their outcome 
as this might be a more cost- effective approach to 
delivering care with limited resources. We, therefore, 
aim to determine if ALC is a predictor of case fatality 
and length of hospital stay in patients admitted with 
COVID-19.
METHODS
We conducted an observational follow- up study at the 
Aga Khan University Hospital (AKUH) from 26 February 
2020 (index case in Pakistan) to 30 June 2020. All cases of 
COVID-19 admitted according to ALC (low, intermediate 
or high) during this period were followed up for case 
fatality and length of hospital stay. A total of 822 adult 
patients included (aged older than >18 years) with posi-
tive reverse transcription polymerase chain reaction for 
COVID-19 were admitted from the emergency room or 
through clinics to the COVID-19 diagnostic and testing 
zone of the hospital. Patients admitted to services other 
than internal medicine (eg, surgical or obstetrics due 
to urgent surgical needs for preoperative screening for 
COVID-19) were excluded (n=123) and 699 patients were 
categorised into low, intermediate or high acuity care 
level.
ALC was categorised as low, intermediate or high 
level according to CDC, USA, for management of 
COVID-19.16 Low acuity level care or general ward 
care is defined as a dedicated ward for patients with 
COVID-19 who require hospital care or oxygen admin-
istration but do not have severe disease. Oxygen 
administration via nasal cannula/mask of maximum 4 
L/min with intermittent monitoring of oxygen satura-
tion and breathing frequency 3–4 times per day, inter-
mediate care or SCU are defined as units dedicated for 
patients who require oxygen therapy and continuous 
monitoring of vital parameters (at least SpO2, ideally 
blood pressure, heart rate and respiratory rate). 
Oxygen administration is done via nasal cannula/
probe, venturi mask or reservoir mask. In ideal circum-
stances, the use of high- flow oxygen therapy and non- 
invasive ventilation (NIV) is not recommended in 
general or outside of an intensive care unit due to the 
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risk of aerosols and of rapid deterioration in the case 
of system failure.21 However, in the intermediate care 
unit in the AKUH, NIV is used in intermediate care 
beds as there is a limited capacity of Intensive care unit 
(ICU) beds. Intensive or high acuity care is dedicated 
to patients who have increasing organ dysfunction 
(eg, increasing respiratory failure) or require invasive 
ventilation or 1:1 nursing. Table 1 demonstrates the 
specification of the three ALC.
The decision of placing the patients into the different 
ALC was based on the standard ESI.15 According to 
the triage process, patients with systolic blood pres-
sure <100 mm Hg, or diastolic blood pressure <60 mm 
Hg, or heart rate >100 beats per minute, or oxygen 
saturation <92%, or who had altered mental status, 
or had respiratory rate >24 breaths per minute were 
considered as unstable and were admitted to interme-
diate acuity level. If unstable patients required inva-
sive ventilation or invasive haemodynamic monitoring, 
they were admitted to high acuity care. However, 
when high acuity care beds were not available, those 
patients who were impending invasive ventilation (on 
more than 8 L oxygen and required continuous NIV) 
or required limited haemodynamic monitoring (only 
central venous pressure monitoring) were admitted 
to intermediate care units instead. The outcome of 
case fatality and length of stay were extracted through 
the hospital information management system and the 
COVID-19 diagnostic and testing zone daily log.
Age, sex and comorbidity of hypertension, diabetes, 
ischaemic heart disease and chronic lung disease 
(asthma and chronic obstructive lung disease) were 
recorded and considered as confounders. Data on 
patients who required invasive ventilation during 
inpatient stay (which required shifting to high- level 
acuity) were recorded. The data were extracted from 
the daily automated admission log of the COVID-19 
diagnostic and testing zone which was maintained by 
head nurses of the respective units. Additionally, for 
validation of the data, the COVID-19- related code 
07982 was extracted from the hospital information 
and management system based on the International 
Classification of Disease-9 coding (ICD-9), as well as 
data on comorbid conditions: hypertension (ICD-9: 
4019), diabetes (25000–25093), ischaemic heart 
disease (41001–41091), asthma (49390–49392) and 
chronic obstructive lung disease (49121), ventilation 
(96.71 and 96.72).
Analysis
For the descriptive statistics, the mean (SD) or median 
(IQR) as appropriate was used for continuous variables 
and frequency and percentages for categorical variables. 
The χ2 test, analysis of variance and Kruskal- Wallis test 
were used as appropriate to compare the three levels of 
acuity and a p value of <0.05 was considered statistically 
significant. The ALC on admission was considered for 
ascertaining the level of acuity. If there was a change in 
acuity level, only the acuity level on admission was consid-
ered. The case fatality ratio (CFR), that is, the propor-
tion of individuals diagnosed with COVID-19 concerning 
those who died of COVID-19 was used as a measure of 
severity among detected cases (CFR=Number of deaths 
from COVID-19/number of confirmed cases of COVID-19 
disease×100).22 Time- to- event (death) analysis was 
performed using Cox regression. Endpoints considered 
were time of fatality, end of inpatient stay or end of the 
study period. Time to event was calculated in days, that is, 
number of days from admission date to date of in- hospital 
death, discharge or end of the study period. Models were 
constructed for the association of acuity level, adjusting 
for age and sex in model 1, and further adjustment for 
comorbid conditions in model 2. Linear regression was 
used to determine the association between acuity with 
a length of stay using a similar modelling strategy HR 
and beta coefficients with corresponding 95% CIs were 
reported. Statistical package for social sciences V.22 was 
used for all analyses.
RESULTS
Characteristics of the patients with COVID-19 are shown 
in table 2. The mean age was 54.5 years and 67% were 
males. A quarter of the patients were in the age range 
Table 1 Characteristics of the three levels of acuity at the Aga Khan University Hospital
Characteristics of care Low- level acuity Intermediate- level acuity High- level acuity
Emergency severity illness score Stable patients* (P3) Unstable and critical patient† 
(P2)
Critical and life- threatening 
patient (P1)
Vitals monitoring Every 6 hours Continuous monitoring Continuous monitoring
Nurse- to- patient ratio 1:5 1:3–4 1:1
Doctor- to- patient ratio 1:8 1:4 1:3
Non- invasive ventilation available No Yes Yes
Invasive ventilation available No No Yes
Cost in US$/day 154 193 290
*Requiring hospital admission or oxygen.
†If unstable patients remain critical in the emergency room, they were initially admitted to high acuity.
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51–60 years. Mean (SD) of the age of patients admitted 
to intermediate care units was higher (59 (14) years) 
than those admitted in low acuity care (50.7 (16) years) 
or high acuity care (56 (11) years). Forty- five per cent of 
the patients aged >60 years were admitted in intermediate 
acuity care, followed by 36% in high acuity and 28% in 
low acuity care. Diabetes was the most common comorbid 
condition (34%) and 9.0% of patients required invasive 
ventilation. Among comorbid conditions, more patients 
with diabetes (42.4%) were admitted to intermediate 
care and more patients with ischaemic heart disease were 
admitted in high acuity care.
Acuity level of care
Most of the patients were admitted to low acuity care 
(50.4%), followed by intermediate (42.5%) and 7.2% to 
high acuity care. The patients requiring a higher level of 
acuity (intermediate and high) were older than those in 
low acuity care (table 2).
Figure 1 demonstrates the trend of patients admitted 
with confirmed COVID-19 from 26 February to 30 
June. There was a rise in admissions to low- level and 
intermediate- level acuity (28 to 179 in low acuity care and 
7 to 136 in intermediate acuity care, respectively), while 
the number of admissions in high- level acuity remained 
similar throughout the period. Also, at least 17% of 





n=352 (50.4%) n=297 (42.5%) n=50 (7.2%)
N (%) n (%) n (%)
Mean (SD) age 54.5 (15.4) 50.7 (16) 59 (14) 56 (11) <0.001
Age group (in years)
  18–30 60 (8.6) 48 (13.6) 11 (3.7) 1 (2)
  31–40 76 (10.9) 49 (13.9)) 22 (7.4) 5 (10)
  41–50 128 (18.3) 76 (21.6) 42 (14.1) 10 (20)
  51–60 178 (25.5) 78 (22.2) 84 (28.3) 16 (32)
  61–70 151 (21.6) 61 (17.3) 77 (25) 13 (26)
  >70 106 (15.2) 40 (11.4) 61 (20.5) 5 (10) <0.001
Sex
  Male 473 (67.7) 233 (66.2) 204 (68.7) 36 (72)
  Female 226 (32.3) 119 (33.8) 93 (31.3) 14 (28) 0.6
Comorbidity
  Diabetes 236 (33.8) 92 (26.1) 126 (42.4) 18 (36) <0.001
  Hypertension 219 (31.3) 100 (28.4) 104 (35.0) 15 (30) 0.1
  Ischaemic heart disease 84 (12) 24 (6.8) 47 (15.8) 13 (26) <0.001
  Chronic lung disease 39 (5.6) 19 (5.4) 18 (6.1) 2 (1) 0.8
  Required non- Invasive ventilation 159 (22.7) 18 (5.1)* 128 (43.1) 13(26) <0.001
  Required invasive ventilation 64 (9.2) 7 (2)† 28 (9.4)† 29 (58) <0.001
  Case fatality ratio 81 (11.6) 7 (2) 48 (16.2) 26 (52) <0.001
  Mean length of stay (SD) 7.26 (6.3) 5.3 (5.3) 8.3 (5.7) 14.2 (9.1) <0.001
  Median length of stay (IQR) 6 (3–9) 4 (2–7) 7 (4–11) 12 (8–19) <0.001
*Shifted to higher care later or applied with palliative intent.
†Patients were moved to a high acuity level during their stay if they required invasive ventilation; the acuity level on admission was used in the 
analysis.
Figure 1 The trend of monthly admissions of confirmed 
patients with COVID-19 according to acuity level at Aga Khan 
University Hospital internal medicine unit (N=699).
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patients fulfilled the criteria for being admitted to high 
acuity care but were instead admitted to intermediate 
care due to limited availability of high acuity beds. These 
were mainly those who were impending invasive ventila-
tion (on more than 8 L of oxygen and required contin-
uous NIV) or who needed limited invasive central venous 
pressure monitoring.
Case fatality
Overall CFR was 11.6%. Comparing the case fatality 
between the three ALC showed that it was highest in the 
high acuity level patients (52%), followed by interme-
diate acuity level patients (16.2%) and 2% among low 
acuity care patients (table 2). Out of the 17% patients 
(141) who required high acuity care but were admitted to 
intermediate acuity care mentioned above, 71% (n=100) 
survived and 29% (n=41) succumbed to death by the end 
of the inpatient stay. In the univariate analysis, the HR 
(95% CI) was 6.7 (95% CI 2.8 to 15.9) for high acuity 
and 4.6 (95% CI 2.0 to 10.2) for intermediate acuity care 
compared with low acuity care. Among the covariates, 
age >70 years (HR=5.0), diabetes (HR=1.9), ischaemic 
heart disease (HR 3.0) and requiring invasive ventilation 
(HR=2.6) were associated with fatality. In the multivariate 
analysis after adjusting for age and sex, increased risk for 
death remained for intermediate acuity (HR 3.4) and 
high acuity care (HR 6.5) and after further adjustment 
of comorbidity in the final model (table 3). The monthly 
trend of CFR is shown in figure 2. For subgroup analyses 
of low ALC with mortality, the HR (95% CI) was 0.30 
(95% CI 0.1 to 0.6) after adjusting for age, sex and comor-
bidities including diabetes, hypertension, ischaemic heart 
disease and chronic lung disease. There was no associa-
tion of comorbidities with mortality in those admitted 
to low acuity care (p value 0.05 for chronic lung disease, 
p value 0.4 for hypertension, p value 0.07 for ischaemic 
heart disease and p value 0.2 for diabetes).
Table 3 Effect of level of acuity cares on fatality in patients with COVID-19, HR and 95% CIs (N=699).
Univariate
Multivariate
Model 1* Model 2†
HR (95% CI) HR (95% CI) HR (95% CI)
Acuity level of care
  Low Ref Ref Ref
  Intermediate 4.6 (2.0 to 10.2) 3.4 (1.5 to 7.6) 2.7 (1.2 to 6.4)
  High 6.7 (2.8 to 15.9) 6.5 (2.7 to 15.5) 5.0 (2.0 to 12.1)
Age group (in years)
  18–30 Ref
  31–40 1.2 (0.2 to 6.5)
  41–50 0.5 (0.1 to 3.4)
  51–60 2.4 (0.5 to 10.6)
  61–70 2.2 (0.5 to 9.6)
  >70 5.0 (1.2 to 21.3)
Sex 0.9 (0.5 to 1.5)
Diabetes 1.9 (1.2 to 3.1)
Hypertension 0.8 (0.5 to 1.4)
Ischaemic heart disease 3.0 (1.9 to 4.8)
Chronic lung disease 0.8 (0.3 to 2.0)
Required invasive ventilation 2.6 (1.6 to 4.2)
*Adjusted for age and sex.
†Adjusted for age, sex and comorbidity including diabetes, hypertension, ischaemic heart disease and chronic lung disease.
Figure 2 The trend of case fatality ratio of patients with 
COVID-19 according to acuity level at Aga Khan University 
Hospital internal medicine unit (N=699).
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Length of hospital stay
The overall average length of stay in the hospital was 7.26 
days (table 1). The overall median (IQR) was 6 (IQR 
3–9) days. Comparing the three acuity levels, it was the 
longest for high- level acuity (14.2 days). In univariate 
analysis, the beta coefficient (95 % CI) was 8.8 (95% CI 
7.1 to 10.5) for high acuity and 2.9 (95% CI 2.0 to 3.8) for 
intermediate care. Among the covariates only requiring 
invasive ventilation was associated with prolonged length 
of stay (beta 7.0 (5.4, 8.5)). In the multivariate analysis 
of acuity level with a length of stay, the association was 
increased for intermediate acuity (beta 2.7 (95% CI 1.8 
to 3.7)) and high acuity care (beta 8.7 (95% CI 6.9 to 
10.4)) after adjustment for age and sex. The association 
remained also after considering comorbidity (table 4). 
The monthly trend of an average length of stay among 
different acuity levels is shown in figure 3. On average, 
there was a 1- day reduction in overall length of stay from 
February to June and a 1- day reduction in length of stay 
in intermediate care.
DISCUSSION
In this study, we found that the case fatality of patients 
with COVID-19 in our setting was highest in the high 
acuity care followed by intermediate care and low acuity 
care. The outcome was favourable (lower case fatality) of 
critical patients admitted to intermediate care compared 
with high acuity care as high acuity care beds are limited. 
This association was independent of age, sex and high- 
risk comorbid conditions including diabetes, hyperten-
sion, ischaemic heart disease and chronic lung disease. 
This supports the fact that the severity of the disease at 
the time of admission and triage into the respective care 
level is a strong predictor of case fatality in this patient 
population. A similar association was found for the length 
of hospital stay. The study signifies the importance of 
initial triaging of patients with COVID-19 into appro-
priate acuity levels as a predictor of outcome.
The comparable CFR in the intermediate care units 
implies that most patients were well managed and were 
able to reduce the need for high acuity care in such a 
resource- limited situation.23 A meta- analysis of 10 clinical 
studies from China on 1995 cases of COVID-19 reported 
a CFR of 5%.24 Mortality in COVID-19 patients has also 
been reported as high as 28%–30% from different regions 
including China and the USA.17 25 At the beginning of the 
pandemic, several European countries reported higher 
mortality of the initially diagnosed cases, up to 25.6%,26 
and several prognostic factors were highly associated with 
mortality, for example, older age and other prognostic 
scores such as sequential organ failure assesment, CURB-
6526 or Pneumonia Severity Index,27 which could help 




Model 1* Model 2†
Beta (95% CI) Beta (95% CI) Beta (95% CI)
Acuity level of care
  Low Ref Ref Ref
  Intermediate 2.9 (2.0 to 3.8) 2.7 (1.8 to 3.7) 2.9 (1.9 to 3.8)
  High 8.8 (7.1 to 10.5) 8.7 (6.9 to 10.4) 8.9 (7.1 to 10.6)
Age (in years) 0.04 (0.01 to 0.07)
Sex 0.7 (-0.2 to 1.7)
Diabetes 0.06 (0.4 to 2.4)
Hypertension 1.4 (0.4 to 2.4)
Ischaemic heart disease 1.4 (−0.006 to 2.8)
Chronic lung disease 1.4 (−0.6 to 3.4)
Required invasive ventilation 7.0 (5.4 to 8.5)
*Adjusted for age and sex.
†Adjusted for age, sex and comorbidity including diabetes, hypertension, ischaemic heart disease and chronic lung disease.
Figure 3 The average length of stay of patients with 
COVID-19 according to acuity level at Aga Khan University 
Hospital internal medicine unit (N=699).
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improve the prognosis value of the ALC at triage as they 
are easy and quick to calculate. Across European countries, 
the CFR has been reported to be around 5%–20%.28–31 
Case fatality varies depending on the population source.29 
According to the official government portal of Pakistan 
capturing population- based data, the overall mortality 
for COVID-19 in Pakistan was 2.1% and in Sindh (the 
southern province in which Karachi is located) was 1.8%.5 
In this study, the overall case fatality from hospital- based 
data was 11%, which is comparable and even lower than 
the mortality reported from hospitals of upper- middle- 
income countries. CFR from hospital settings in India, 
a neighbouring country with a similar genetic, ethnic 
and cultural background, was reported to be 28%.32 The 
reason for the variation in case fatality across the globe 
might be linked to underdetection of mild or asymp-
tomatic cases or differences in medical care.33 Of note, 
changes in the management of COVID-19 over time with 
steroids and other trial drugs such as remdesivir and 
tocilizumab might have also impacted case fatality over 
time.34 35 Additionally, our centre is a tertiary care centre 
and the first one to treat patients with COVID-19 in Paki-
stan, hence a significant number of patients presented 
with moderate- to- severe disease due to delayed presenta-
tion from within and outside Karachi. Other mechanisms 
including genetics, immunity and environmental factors 
need further exploration.
While many studies report the outcomes of COVID-19 
based on the severity of the disease, comparatively fewer 
studies present the CFR among the different ALC of 
patients at admission. In a study from Italy on 174 non- 
critical COVID-19 patients, the CFR reported was 2.5%.29 
This is identical to our rate for those who were initially 
admitted to low acuity care. Although high- flow oxygen 
therapy and NIV are not recommended in general and 
outside of an intensive care unit.21 NIV support techniques 
have been used to develop a respiratory intermediate care 
unit to implement non- invasive oxygenation in France.36 
NIV is beneficial in the initial management of acute respi-
ratory distress syndrome associated with SARS- CoV-2, 
particularly in times of ICU shortage. The same strategy 
was used in our intermediate care units by using NIV and 
hence preventing early intubation where justified. Data 
from an observational study on 670 consecutive patients 
with confirmed COVID-19, managed in an out- of- ICU 
setting, in nine hospitals showed an unadjusted mortality 
rate of 26.9%; the patients in these units were managed 
with high- flow nasal cannula, NIV or continuous positive 
airway pressure.37 The CFR from our intermediate care 
unit was 16%, thus lower than reported in the former 
study. The reason for this could be that our medical staff 
was accustomed to managing patients on NIV in a respi-
ratory unit even before the COVID-19 pandemic, hence 
they might be more skilled in managing acute respiratory 
distress syndrome and hypoxia.38 Second, due to resource 
limitations in intubation of patients, we might have used 
NIV for longer periods or maintained a higher threshold 
for intubation. Third, our respiratory units for patients 
with COVID-19 were primarily managed by an internist 
and pulmonologist who were involved in consultations. 
As internists have experience in managing patients with 
multimorbidity and have a holistic approach in managing 
patients, this might have improved the overall outcome of 
these patients. For example, patients with COVID-19 are 
more likely to have uncontrolled diabetes and for better 
outcomes good glycaemic control is essential.39 A meta- 
analysis on 14 studies on 4659 patients reported diabetes 
and ischaemic heart disease as predictors of mortality in 
patients with COVID-19 in addition to other inflamma-
tory and clinical parameters.40 In another meta- analysis of 
6452 patients from 30 studies, diabetes mellitus doubled 
the risk of mortality in patients with COVID-19 and so did 
ischaemic heart disease.41 42 In the current study, having 
diabetes or ischaemic heart disease was associated with 
increased fatality. Hence, our findings are in alignment 
with the former research findings.
For patients admitted to ICUs, the case fatality had been 
reported to be around 40%–50% in the USA.43 44 Data 
from six COVID- designated ICUs from Atlanta, Georgia, 
USA, (n=217) demonstrated mortality of 35.7%.45 
Our CFR is 50% which is comparable to what has been 
reported from other regions. This relatively higher case 
fatality could be due to severe disease and delayed presen-
tation to the hospital due to limited critical care facilities 
in the city. Second, it might also be linked to the different 
South Asian backgrounds of the patient population.46 In 
contrast, mortality rates reported from Washington, USA, 
(n=21) were as high as 67%.47 It is useful to note here that 
despite being an LMIC the care provided to patients with 
COVID-19 was comparable to that provided in certain 
high- income countries. There is an urgent need for 
collaborative efforts of ICU practitioners, hospital admin-
istrators, governments and policy- makers to prepare for 
a substantial increase in critical care bed capacity, with 
a focus on infrastructure, supplies and staff manage-
ment.23 The Sindh government is collaborating with the 
AKUH to provide free training and technical assistance to 
healthcare professionals working in the public sector in 
providing critical care to patients with COVID-19.48
Addressing CFR according to age indicates that it 
ranges from 3.5% to 20% among those aged >60 years in 
Italy and 3.6%–14% in the same age range in China.29 49 
Our CFR shows the same trend of being higher in those 
aged >than 60 years. However, these CFR figures might be 
overestimated as our data are based on clinical data and 
are not population based. The higher CFR in the older 
population might also be because they were not subjected 
to invasive ventilation due to poorly predicted outcomes 
associated with old age, frailty, comorbidities or logistic 
limitations due to the non- availability of ventilated beds.18 
Also, the risk of having a critical disease is higher in indi-
viduals having age above 50 years or those having comor-
bidities, hence requiring higher ALC. This might be one 
reason that more elderly population was admitted in 
intermediate acuity level rather than low or high acuity 
level in this study.
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Regarding the length of hospital stays due in patients 
with COVID-19, a systematic review of 52 studies reported 
a median length of hospital stay ranging from 4 to 53 days 
in China and 4 to 21 days outside of China.19 For an ICU 
stay, it was 14 days within China and 7 days (4–11) outside 
China. The review further stated that the length of stay 
was longer for those who survived versus those who did 
not survive. Our overall median length of stay was 6 days 
with an IQR of 3–9 days, which is significantly lower than 
what is reported from China, although the median ICU 
stay was similar, 12 (IQR 8–19), and similar to ICU stays 
elsewhere. A potential reason for a considerably lower 
median stay in non- critical patients might be that the 
pandemic lagged behind in countries outside of China, 
which might have provided ample opportunity for these 
countries to use trial drugs including steroids, tocili-
zumab and remdesivir which potentially contributed to 
improved outcomes.50–52
The strength of our study is that it is the first of its kind 
to report the association between ALC of patients with 
COVID-19 and CFR from a hospital in an LMIC. This centre 
is the pioneer hospital in a city of 17 million people that 
started treating critical patients with COVID-19, hence the 
results do have implications as a guidance for other hospi-
tals that treat patients with COVID-19. The study was able 
to adjust not only for the bias of confounding by sex and 
age but also for important comorbidities. Nonetheless, 
there are several limitations to the study. This is a single- 
centre study; hence, the results are not generalisable to 
the entire population. Also, the severity of patients based 
on radiological and laboratory parameters has not been 
reported in this study as we relied on data regarding acuity 
level. Also, only a limited number of common comorbid 
conditions were investigated and compared across acuity 
levels and mortality; expanded clinical datasets would be 
beneficial to investigate for further research. We also did 
not report data on different drugs that were used in the 
treatment of COVID-19.
CONCLUSION
High and intermediate acuity levels are associated with 
higher CFRs and prolonged length of hospital stay in 
patients with COVID-19 compared with patients admitted 
to low acuity levels. In resource- limited settings where the 
provision of high acuity care is limited, the intermediate 
care acuity could serve as a useful strategy to treat rela-
tively less critical patients with COVID-19. It is important 
to accurately triage patients with COVID-19 based on the 
level of care as improvements in clinical outcomes and 
overall survival depends on it. In LMIC such as Paki-
stan, government and private sector hospitals can aim 
to develop more intermediate care units in addition to 
intensive care units for useful and cost- effective care of 
patients.
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